Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.71 |
| ▸ | HSP90AB1 | P08238 | 8/20 | 0.71 |
| ▸ | AGPAT2 | O15120 | 9/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942089 | 0.87 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1AGPAT2 | |
| SCHEMBL3952206 | 0.85 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1AGPAT2ALDH1A1 | |
| SCHEMBL5375905 | 0.85 | AGPAT2 (0.67) | HSP90AA1HSP90AB1AGPAT2ALDH1A1KDM4E | |
| SCHEMBL4286869 | 0.84 | AGPAT2 (0.70) | HSP90AA1HSP90AB1AGPAT2 | |
| SCHEMBL3718236 | 0.83 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1AGPAT2KDM4E | |
| SCHEMBL4286846 | 0.83 | ALDH1A1 (0.55) | HSP90AA1HSP90AB1AGPAT2ALDH1A1KDM4E | |
| SCHEMBL15756953 | 0.83 | AGPAT2 (0.77) | HSP90AA1HSP90AB1AGPAT2ALDH1A1KDM4E | |
| SCHEMBL5386005 | 0.83 | ALDH1A1 (0.57) | HSP90AA1HSP90AB1AGPAT2ALDH1A1KDM4E | |
| SCHEMBL13880138 | 0.81 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL9566471 | 0.80 | RECQL (0.78) | HSP90AA1HSP90AB1AGPAT2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-1991550-A1 | AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome Limited (GB) | 2008-11-19 | — | — | EP | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1860109-A1 | Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1860109-A1 | Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1860108-A1 | Enantiomers of Amino Pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1860108-A1 | Enantiomers of Amino Pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1829879-A1 | Amino pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829879-A1 | Amino pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007090854-A1 | AZETIDINE AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090854-A1 | AZETIDINE AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090853-A1 | ENANTIOMERS OF AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090852-A1 | AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090853-A1 | ENANTIOMERS OF AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090852-A1 | AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | HSP90AA1 4126/4885HSP90AB1 4236/4885AGPAT2 100/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | HSP90AA1 4006/4885HSP90AB1 3829/4885AGPAT2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.